Vertex Pharmaceuticals (NasdaqGS:VRTX) reported strong Q4 results, reflecting continued execution on its broader portfolio beyond cystic fibrosis. The company is ramping up CASGEVY gene-editing ...
Europe’s health regulator followed the United States and the United Kingdom in backing the first gene-editing therapy to use Crispr technology, a Vertex Pharmaceuticals Inc. and Crispr Therapeutics AG ...
Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...
Gene therapy and gene editing are marvels of modern biotechnology, providing revolutionary techniques for fixing genetic abnormalities. Gene therapy introduces functional genetic material to ...
We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other best ...
After reaching FDA first, CRISPR-Vertex's gene editing therapy will get 'benign' review by committee
A historic moment in pharmaceuticals will happen next week: an FDA advisory committee is set to review the first-ever CRISPR gene editing-based therapy, Vertex Pharmaceuticals and CRISPR Therapeutics’ ...
July 15 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab sued the U.S. Department of Health and Human Services on Monday, seeking a court declaration that a fertility support program for ...
Vertex Pharmaceuticals (NASDAQ:VRTX) announced Tuesday that the U.S. FDA approved its groundbreaking gene editing therapy, Casgevy, developed with CRISPR Therapeutics (NASDAQ:CRSP) for those aged 12 ...
Vertex was once known for discovering Incivek, a blockbuster hepatitis C drug now overshadowed by a robust cystic fibrosis franchise with megablockbuster potential. The company's approved cystic ...
WATCH: The breakthrough treatment, made by local drug firms, targets sickle cell disease. Reporter Jonathan Saltzman breaks down the life-changing medicine. Marie Tornyenu missed more than 100 days of ...
Europe’s health regulator followed the US and UK in backing the first gene-editing therapy to use Crispr technology, a Vertex Pharmaceuticals Inc. and Crispr Therapeutics AG treatment for sickle cell ...
A U.S. flag flies next to the headquarters of Vertex in Boston (Reuters) -Vertex Pharmaceuticals sued the U.S. Department of Health and Human Services on Monday, seeking a court declaration that a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results